New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
07:42 EDTEPZMEpizyme initiates pediatric MLL-r proof-of-concept study for leukemia candidate
Epizyme initiated a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene. This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Expected data disclosure date is in 2H14.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
08:05 EDTEPZMEpizyme presents EPZ-6438 pre-clinical data
Subscribe for More Information
October 10, 2014
08:02 EDTEPZMEpizyme announces presentation of EPZ-6438, EPZ-5676 data
Epizyme announced that clinical and pre-clinical data on its histone methyltransferase inhibitors will be highlighted in oral and poster presentations at the 56th annual meeting of the American Society of Hematology to be held December 6-9 in San Francisco, California. The company will present data from EPZ-5676 and EPZ-6438 studies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use